Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN)
09.09.2026 -
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
09.09.2026 -
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
09.09.2026 -
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount
09.09.2026 -
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
04.09.2026